Hematologic Oncology

Basem William, MD, MRCP, FACP, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.

Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.

Tisagenlecleucel maintained strong rates of response and duration of response in adults with relapsed/refractory diffuse large B-cell lymphoma, according to the latest findings from the phase II JULIET study presented at the 2019 SOHO Annual Meeting.

John F. DiPersio, MD, PhD, discusses the challenges in research surrounding targeted cellular therapies for acute myeloid leukemia

The use of checkpoint inhibitors prior to haploidentical stem cell transplantation improved progression-free survival and reduced the risk for relapse for patients with relapsed or refractory Hodgkin lymphoma, according to results from a retrospective study presented at the 2019 SOHO Annual Meeting.

Maintenance therapy with CC-486 (oral azacitidine) led to a highly statistically significant and clinically meaningful improvement in overall survival compared with placebo in patients with newly diagnosed acute myeloid leukemia who achieved first complete response or CR with incomplete blood count recovery with induction therapy.

Novel strategies are needed to enhance the efficacy of CAR T-cell therapies in patients with acute lymphoblastic leukemia, including new constructs that target more than 1 antigen.

Steven T. Rosen, MD, Irell & Manella Cancer Center Director's Distinguished Chair, Morgan & Helen Chu Director's Chair of the Beckman Research Institute, provost and chief scientific officer, director of the Comprehensive Cancer Center, Beckman Research Institute, and Irell & Manella Graduate School of Biological Sciences, and professor in the Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope, discusses the emergence of novel therapies and the incorporation of immuno-oncology (IO) drugs in hematologic malignancies.

Mitchell R. Smith, MD, PhD, professor of medicine, George Washington University, associate center director for clinical investigations, Division of Hematology and Oncology, GW Cancer Center, discusses emerging therapeutic approaches in indolent lymphoma.

David S. Snyder, MD, associate chair, Department of Hematology and Hematopoietic Cell Transplantation, professor, Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses ongoing research in myelofibrosis.

Mark James Levis, MD, PhD, program leader of Hematologic Malignancies and Bone Marrow Transplant Program at Sidney Kimmel Comprehensive Cancer Center, and professor of oncology, Johns Hopkins Medicine, discusses an analysis of gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia harboring other common co-mutations or a high FLT3-internal tandem duplication allelic ratio.

Steven T. Rosen, MD, discusses the rapid evolution in hematologic cancer treatment and highlighted challenges that have recently emerged.

Experts from City of Hope share insight on some of the pivotal research being conducted at their institution.

David S. Snyder, MD, highlights agents currently undergoing clinical trials for polycythemia vera and myelofibrosis as well as how to most effectively treat patients using transplantation.

Phillippe Moreau, MD, head, Hematology Department, university professor of clinical hematology, University Hospital of Nantes, France, discusses the phase III CASSIOPEIA trial in transplant-eligible multiple myeloma.

Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase I/II trial of tagraxofusp (SL-401; Elzonris) in patients with intermediate- or high-risk relapsed/refractory myelofibrosis.

Jorge E. Cortes, MD, deputy chair and professor of medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses The 192-week follow-up results of the ENESTop trial in chronic myeloid leukemia.

Robert L. Redner, MD, a medical oncologist and hematologist, and professor of medicine, at the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, discusses the activity of venetoclax (Venclexta) in acute myeloid leukemia (AML).

James K. McCloskey II, MD, discussed current treatment options for patients with myelofibrosis as well as further options in development in clinical trials.

Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA Health, discusses the need for long-term outcome data pertaining to treatment discontinuation in chronic myeloid leukemia (CML).